Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trialMassimiliano Fabbiani, Gabriella d’Ettorre, Andrea Antinori et al.|Journal of Antimicrobial Chemotherapy|2018Cited by 33
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study)Massimiliano Fabbiani, Simona Di Giambenedetto, Annalisa Mondi et al.|Scandinavian Journal of Infectious Diseases|2013Cited by 29
HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjectsMassimiliano Fabbiani, Simona Di Giambenedetto, Letizia Sidella et al.|Vaccine|2013Cited by 19